MetaVia Inc. announced positive, statistically significant results from its Phase 1b clinical trial of DA-1726, a novel dual oxyntomodulin analog agonist for the treatment of obesity and metabolic disease. The 8-week, non-titrated 48 mg multiple ascending dose cohort demonstrated a 9.1% reduction in body weight (21.2 lbs), a 9.8 cm reduction in waist circumference, a 12.3 mg/dL reduction in fasted glucose, and a 23.7% reduction in liver stiffness by Day 54. The study reported a favorable safety and tolerability profile, with no treatment-related discontinuations. The results have already been announced by the company. Additional details can be found at www.clinicaltrials.gov under NCT06252220.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY55885) on January 05, 2026, and is solely responsible for the information contained therein.